"Harmonize Drug Policy," SADC States Are Urged

16 June 1996

Countries of the Southern African Development Community have been urged to harmonize their drug policies in order to protect consumers from dangerous medicines.

Norman Nyazema, a clinical lecturer at the University of Zimbabwe, has spoken out strongly on the vulnerability of countries in the region which are heavily dependent on drug imports and thus vulnerable to dumping. According to a report from the Xinhua news agency, Prof Nyazema warned that in the absence of clear-cut policies, "obsolete, ineffective, dangerous or irrational combinations of drugs" would find a market in some countries. "In the SADC region there is an urgent need to harmonize drug legislation and regulation, for exchange of information among regulatory authorities and enforcement of consumer protection laws," he added, warning that some drugs donated to a number of developing countries had been found to be "either nearing expiry or outright useless."

What Prof Nyazema failed to mention, however, is that many of these dubious drugs emanate from the African continent, and in so far as drug donations are concerned, very often medicines pass their sell-by-date not at the originator but because they have been left in docksides of warehouses rather than been distributed promptly to people who need them. Ed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight